A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia [0.03%]
Meta分析评价表皮生长因子受体酪氨酸激酶抑制剂单药治疗与以铂类为基础的双药化疗在东亚人群中的安全性和有效性
X F Zhang,L V De-Sheng,M Li et al.
X F Zhang et al.
Objective: Several clinical trials have shown that advanced nonsmall cell lung cancer (NSCLC) patients can benefit from treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy than...
Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line [0.03%]
印度晚期非小细胞肺癌一线、维持和二线治疗共识声明
Under the aegis of Lung Cancer Consortium Asia (LCCA);Indian Cooperative Oncology Network (ICON);Indian Society of Medical & Pediatric Oncology (ISMPO);Molecular Oncology Society
Under the aegis of Lung Cancer Consortium Asia (LCCA);Indian Cooperative Oncology Network (ICON);Indian Society of Medical & Pediatric Oncology (ISMPO);Molecular Oncology Society
The management of advanced nonsmall cell lung cancer (NSCLC) patients is becoming complex with the identification of driver mutations and targeted therapies. The expert group of academic medical oncologists used data from published literatu...
T Puri
T Puri
Activating mutations in the epidermal growth factor receptor gene and rearrangement of the anaplastic lymphoma kinase gene exemplify the molecular characterization of nonsmall cell lung cancer (NSCLC), particularly adenocarcinoma, and its t...
Fluorodeoxyglucose-avid pulmonary mucinous adenocarcinoma presenting with nonfluorodeoxyglucose-avid cystic brain lesions of unknown etiopathology: Brain magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography-computed tomography imaging features and additional value of whole-body positron emission tomography acquisition [0.03%]
不明原因的脑囊变病灶未见18F-FDG摄取伴18F-FDG阳性肺粘液腺癌的影像学特征及全身PET显像的附加价值：一例报告及文献复习
V Shinde,S Basu
V Shinde
Is pneumonectomy a justified procedure in patients with persistent N2 nonsmall cell lung cancer disease following induction therapy [0.03%]
诱导治疗后持续存在N2期非小细胞肺癌的患者行肺叶切除术是否合理？
S Mitsos,M Petko,D Patrini et al.
S Mitsos et al.
Optimal management and the role of surgery in multimodality treatment for N2 disease nonsmall cell lung cancer (NSCLC) are controversial. In this review, we focus on the possible role of pneumonectomy as a justified procedure in patients wi...
Mediastinal staging for non-small cell lung cancer revisited. It is being done under aegis of ICON and Lung cancer consortium asia [0.03%]
非小细胞肺癌的纵隔分期再评估(icon和亚洲肺癌联盟发起)
D Pandey,P Ramanathan,R Pandey et al.
D Pandey et al.
Mediastinal staging is a crucial factor in the decision making in patients with non-metastatic non-small cell lung cancer (NSCLC). Mediastinoscopy has historically been the gold standard for this purpose. With the advent of PET-CT, the role...
Metformin use and survival of lung cancer patients: Meta-analysis findings [0.03%]
二甲双胍的使用与肺癌患者的生存率：荟萃分析结果
S Zhong,Y Wu,X Yan et al.
S Zhong et al.
Previous studies on the association between metformin use and lung cancer survival have yielded mixed results. We aimed to perform a metaanalysis to assess the association with all available studies. Relevant studies were identified by sear...
Metastasectomy for recurrent or metastatic biliary tract cancers: A single center experience [0.03%]
复发或转移性胆道癌的转移灶切除术：单中心经验报告
I Park,Y S Kim,S J Sym et al.
I Park et al.
Purpose: To assess efficacy or long-term result of metastasectomy for recurrent or metastatic biliary tract carcinoma (BTC), we conducted a retrospective review of the outcomes of metastasectomy for recurrent or metastati...
Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status [0.03%]
奈沃单抗为低体能状态晚期非小细胞肺癌患者带来无望中的希望
M V Chandrakanth,V Noronha,A Joshi et al.
M V Chandrakanth et al.
Robotic resections in hepatobiliary oncology - initial experience with Xi da Vinci system in India [0.03%]
肝胆肿瘤的机器人切除术——印度达芬奇Xi系统初步经验
M Chandarana,S Patkar,A Tamhankar et al.
M Chandarana et al.
Introduction: Minimal invasive surgery has proven its advantages over open surgeries in the perioperative period. Food and Drug Administration approved da Vinci robot in 2000. The latest version, da Vinci Xi system has a ...